Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of a new resource, Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions.

Subscribe Publication Updates

Publication Updates

08 Oct
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker October 2018 update

New and updated interactions now available

For October, 95 new interactions have been added, and 57 existing interactions have been updated.

08 Oct
Herbal Medicines logo
Herbal Medicines October 2018 update

Horse-chestnut and Parsley Piert have been fully revised. Greater Celandine, Hawthorn, Milk thistle and Passion flower have been selectively revised. Pharmacopoeial, Preparations and Manufacturers information have also been updated.  

Revised monographs: Horse-chestnut and Parsley Piert. 

Selective Revisions: Greater Celandine, Hawthorn, Milk thistle and Passionflower.  

Minor Updates: British Pharmacopoeia, European Pharmacopoeia, and USP-NF information has been globally updated; Appendices 2 and Preparation and Manufacturers information have been updated

08 Oct
Stockley's Herbal Medicines Interactions logo
Stockley’s Herbal Medicines Interactions October 2018 update

Greater Celandine and Horse-chestnut have been revised and Turmeric has been selectively revised. Pharmacopoeial information has also been updated.  

Revised monographs: Greater Celandine and Horse-chestnut. 

Selective Revisions: Turmeric. 

Minor Updates: USP-NF information globally updated.

08 Oct
AHFS Drug Information logo
AHFS Drug Information October 2018 update 

This update contains 7 new monographs, 13 revised monographs and 1 new MedWatch alerts. 

New monographs: Dehydrated Alcohol; Iobenguane I 131; Tildrakizumab-asmn; Patisiran; Tafenoquine; Glycopyrronium; Mogamulizumab-kpkc 

Revised monographs: Nevirapine; Enfuvirtide; Bortezomib; Methylnaltrexone; Regorafenib; Naloxegol; Naldemedine; Cyclophosphamide; DOXOrubicin; Aspirin; metroNIDAZOLE; Azithromycin; Thalidomide 

New MedWatch alerts on the following monographs: Azithromycin

08 Oct
British National Formulary for Children logo
BNFC October 2018 update

This update contains 5 significant changes, 1 dose change and 2 new preparations.

Significant Changes: 

  • Side-effects and their further information sections have been reviewed against the current product literature and terms used to define these have been standardised across all drug monographs for this update.
  • Dinutuximab beta for treating neuroblastoma [NICE guidance].
  • Ear, Ear infections, antibacterial therapy: updated guidance on management of otitis media.
  • Heavy menstrual bleeding: updated guidance on management.
  • Nusinersen (Spinraza®): reports of communicating hydrocephalus not related to meningitis or bleeding [MHRA/CHM advice].

Dose Changes:

  • Rufinamide [update to age range for use in children and dosing information for use with valproate].

New Preparations: Qarziba® [dinutuximab beta]; Xgeva® [denosumab] (BNFC only).   

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

08 Oct
British National Formulary logo
BNF October 2018 update

This update contains 9 significant changes, 2 dose changes and 4 new preparations.

Significant Changes: 

  • Side-effects and their further information sections have been reviewed against the current product literature and terms used to define these have been standardised across all drug monographs for this update.
  • Alectinib for untreated ALK-positive advanced non-small-cell lung cancer [NICE guidance] (BNF only).
  • Dinutuximab beta for treating neuroblastoma [NICE guidance].
  • Dupilumab for treating moderate to severe atopic dermatitis [NICE guidance] (BNF only).
  • Ear, Ear infections, antibacterial therapy: updated guidance on management of otitis media.
  • Heavy menstrual bleeding: updated guidance on management.
  • Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs [NICE guidance] (BNF only).
  • Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [NICE guidance] (BNF only).
  • Nusinersen (Spinraza®): reports of communicating hydrocephalus not related to meningitis or bleeding [MHRA/CHM advice].

Dose Changes:

  • Golimumab [maintenance dose for patients with ulcerative colitis and body-weight less than 80␣kg] (BNF only).
  • Rufinamide [update to age range for use in children and dosing information for use with valproate].

New Preparations: Biktarvy® [bictegravir with emtricitabine and tenofovir alafenamide] (BNF only); Diclofenac mouthwash [diclofenac] (BNF only); Elmiron® [pentosane polysulfate sodium] (BNF only); Qarziba® [dinutuximab beta].           

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

View more